GUIDES

What Is the Evidence?

DACC-Coated Dressings: Leukomed® Sorbact®

Leukomed® Sorbact® can reduce the rate of surgical wound infections, antibiotic usage and associated hospital admissions

■ 65% reduction in SSI risk in postcaesarean section patients2

■ 47% relative risk reduction of SSI in vascular surgery, compared to standard dressings3

■ Leukomed® Sorbact® is cost effective1,2

Caesarean Section Wounds Vascular Surgery Wounds

■ SSI is a common complication following caesarean section, and the procedure has higher rates of this than other surgeries, affecting 1.8 - 9.2% of patients undergoing this procedure2, (Figure 2). The consequences are potentially devastating for the individual and costly for hospitals and healthcare systems

■ The success in use of Leukomed® Sorbact® dressings in the management of surgical wounds of patients following this procedure, to prevent SSI, is well evidenced1

■ Stanirowski et al. conducted a randomized, single-blinded controlled study which assessed the efficacy of Leukomed® Sorbact® in preventing SSI in women after a caesarean section. The participants were randomly assigned to two groups, one given standard surgical dressings and the other group given Leukomed® Sorbact® dressings2

■ Stanirowski notes a decreased rate of SSI in the group given Leukomed® Sorbact® dressings2 (Figure 2)

■ Bua et al. report on a prospective, nonrandomized comparative study in a single vascular surgery center, involving two groups of 100 participants, one which was treated with Leukomed® Sorbact® dressings, and the other group given the standard inert surgical dressings normally used by the clinicians of the facility, concluding:

■ “DACC coated dressings were associated with a significant reduction in SSI rates in the early post-operative period.”3 (Figure 2)

■ “Dialkylcarbamoyl chloride (DACC)coated dressings in the management and prevention of wound infection: a systematic review’ considers 17 studies involving 3408 patients, to conclude that: “DACC-coating of dressings shows promise in both the prevention and treatment of wound infections... the available evidence that is presented is in support of DACC-coated dressings, and such promise does allow for the undertaking of further high-quality research into their clinical and costeffectiveness.”4

Costs

■ Stanirowski notes reduced costs in treatment of the study group treated with Leukomed® Sorbact®, due to reduced need for further treatment resulting from SSI2 (Figure 2)

■ The NICE (The National Institute for Health and Care Excellence) guidance for Leukomed® Sorbact® further supports the cost effectiveness, efficacy and safety in use of Leukomed® Sorbact® dressings1

■ “Hydrophobic dressing application seemed to result in a decreased rate of SSI and a considerably milder course, with no need for systemic antibiotic therapy and hospital readmissions.”

“Total cost of SSI treatment was lower… and was a result of ambulatory visits only.”2

■ “Leukomed Sorbact is cost saving across a wide range of SSI costs, device costs, comparator costs and relative risk reduction.”1

■ “DACC coated hydrophobic dressings have effects in preventing SSI in a number of different patient groups and may have a significant role in future surgical wound management.”3

DACC-Coated Dressings:

Key Points

■ 65% reduction in SSI risk in post-caesarean section patients2

■ 47% relative risk reduction of SSI in vascular surgery compared to standard dressings3

■ Potential for use for other types of surgery, supported by clinical experts1

■ Provides high patient comfort

■ Reliable adhesion; dressing remains securely in place

■ Breathable and showerproof

■ Adverse effects are minor and uncommon1

References

1. NICE. 2021. Leukomed Sorbact for preventing surgical site infection. NICE National Institute for Health and Care Excellence. MTG55

2. Stanirowski PJ, Bizoń M, Cendrowski K, Sawicki W. Randomized Controlled Trial Evaluating Dialkylcarbamoyl Chloride Impregnated Dressings for the Prevention of Surgical Site Infections in Adult Women Undergoing Cesarean Section. Surg Infect (Larchmt). 2016 Aug;17(4):427-35. doi: 10.1089/sur.2015.223. Epub 2016 Feb 18. PMID: 26891115; PMCID: PMC4960475.

3. Bua N, Smith GE, Totty JP, Pan D, Wallace T, Carradice D, Chetter IC. Dialkylcarbamoyl Chloride Dressings in the Prevention of Surgical Site Infections after Nonimplant Vascular

4. Totty JP, Bua N, Smith GE, Harwood AE, Carradice D, Wallace T, Chetter IC. Dialkylcarbamoyl chloride (DACC)-coated dressings in the management and prevention of wound infection: a systematic review. J Wound Care. 2017 Mar 2;26(3):107-114. doi: 10.12968/jowc.2017.26.3.107. PMID: 28277989.

5. Surgery. Ann Vasc Surg. 2017 Oct;44:387-392. doi: 10.1016/j.avsg.2017.03.198. Epub 2017 May 5. PMID: 28483629.

6. Stanirowski PJ, Kociszewska A, Cendrowski K, Sawicki W. Dialkylcarbamoyl chloride-impregnated dressing for the prevention of surgical site infection in women undergoing

7. Caesarean section: a pilot study. Arch Med Sci. 2016 Oct 1;12(5):1036-1042. doi: